MHPG as a predictor of antidepressant response to imipramine and maprotiline.
To explore the hypothesis that depressed patients with low pretreatment levels of urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) respond more favorably to antidepressant drugs which act on noradrenergic neuronal systems than do patients with high MHPG levels, the authors administered 150--200 mg/day of imipramine or maprotiline to 13 depressed patients. All of the 5 patients with low pretreatment MHPG levels responded to treatment compared with 1 of the 14 patients with high MHPG levels; 4 patients dropped out of the study.
D000328:Adult; D000873:Anthracenes / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000652:urine; D005260:Female; D006018:Glycols / Q000652:urine*; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D008376:Maprotiline / Q000627:therapeutic use*; D008734:Methoxyhydroxyphenylglycol / Q000652:urine*; D008875:Middle Aged
D000873:Anthracenes; D006018:Glycols; D008376:Maprotiline; D008734:Methoxyhydroxyphenylglycol; D007099:Imipramine